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the severity of arthritic changes in both cartilage and joint tissue.
However, the inhibition of TNF-a resulted in detrimental bone
morphological changes, loss of cartilage, and inﬂammation of joint
tissue. This study shows a novel reduction in post-trauma inﬂammation
and demonstrates utility for an injectable drug depot for clinical intra-
articular applications in the treatment of joint trauma.
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IDENTIFICATION OF THE PATIENTS WHO RESPOND SAFELY AND
OPTIMALLY TO INTERVENTION WITH BIOLOGICS; LESSON LEARNED
FROM RHEUMATOID ARTHRITIS
A.-C. Bay-Jensen, A. Siebuhr, I. Byrjalsen, C. Christiansen, M.A.
Karsdal. Nordic BioSci. A/S, Herlev, Denmark
Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterized debilitating joint destruction, if not treated aggressively
in the patient in most need of treatment. Personalized health care is
needed and tested in RA, as response rates are low compared to the
potential side effects and cost of treatment. Thus lessons on patient
segregation can be learned and used in other joint diseases, such as
osteoarthritis (OA). We investigated whether tissue-speciﬁc, serum-
based biomarkers measured at baseline or after 1 dose could identify
“super responders” to 4 mg/kg tocilizumab in patients with moderate
to severe RA on a methotrexate background enrolled in the LITHE
study.
Methods: The LITHE biomarker study (n¼740) was a phase III study of 4
and 8mg/kg TCZ in combinationwithMTX. Patients were separated into
ACR50 (week 52) responders and non-responder and serum biomarkers
were measured at baseline and week 4. Following tissue-speciﬁc
biomarkers were measured; C3M (synovial turnover), CRPM (connec-
tive tissue inﬂammation), C2M (cartilage degradation), CTx (bone
resorption), osteocalcin (bone formation), CRP (acute phase reactant)
and MMP3 (proteolytical activity). ROC was use to ﬁnd the optimal cut-
offs for the biomarkers at baseline and change from baseline to week4.
CART analysis was used to segregate patients and 2x2 contingency test
was used for identifying response rates.
Results: A simple combination of 4 baseline markers (C1M, C3M, MMP-
3 and CRPM) increased the response rates (ACR50 at week 52) from 27
to 54%, while restricting the patient population to 22 %. When including
the change from baseline to 4 weeks of cartilage degradation or bone
formation, patient beneﬁt was enriched to 64 %, while allowing
continued treatment of 17% of patients and referral of 92% of the non-
responders earlier to other possible interventions (ﬁgure).
Conclusions: By using a combination of simple serological markers,
response rates were more than doubled in so-called “IL-6 super
responders”. This may assist in identiﬁcation of the patients, in any
inﬂammatory disease, who respond most optimally to given interven-
tions, with fewer AEs, and thus provide a stronger risk/beneﬁt/cost
value proposition to patients and payers.Ă45
IDENTIFICATION OF FIBROBLAST GROWTH FACTOR-18 AS
A MOLECULE TO PROTECT AND REGENERATE ARTICULAR CARTILAGE
Y. Mori y, T. Saito y, C.H. Ladel z, H. Guehring z, U.-i. Chung y, H.
Kawaguchi y. y Sensory & Motor System Med., Univ. of Tokyo, Tokyo,
Japan; zMerck Serono Res., Darmstadt, GermanyPurpose: Aiming at the disease-modifying treatment of osteoarthritis
(OA), we sought to identify genes that maintain the homeostasis of
adult articular cartilage and regenerate its lesions by gene expression
proﬁle analyses.
Methods:We initially performed two sets of microarray analyses. First,
to identify genes involved in maintenance of articular cartilage, we
compared gene expression proﬁles between adult articular (AA) and
adult growth plate (AG) cartilages in 10-week-old rats. Second, to
identify genes involved in regeneration of articular cartilage, we
compared the proﬁles between infant superﬁcial (IS) and infant deep
(ID) layers of epiphyseal cartilage in 6-day-old rats. For genes which
were up-regulated 10-fold both in AA than AG and in IS than ID, we
performed real-time RT-PCR for the conﬁrmation. In vivo expression of
the identiﬁed gene was examined by immunohistochemistry of artic-
ular and growth plate cartilage of 14-week-old rats. The therapeutic
effect was examined in the experimental OA model by surgical induc-
tion of instability in the knee joints of adult rats. To learn the underlying
mechanism, the protective ability of articular cartilage was assessed by
measuring the amount of sulfated glycosaminoglycan (sGAG) released
into the medium in the ex vivo culture of bilateral femoral heads of 3-
week-old mice. Proliferation and migration were analyzed in the
cultures of mouse articular chondrocytes using Cell Counting Kit-8 and
Oris Cell Migration assay systems, respectively. Expression levels of
catabolism-related factors (Mmp9, Mmp13, Adamts4, Adamts5, Timp1,
Timp2, and Timp3) and anabolism-related factors (Col2a1 and aggre-
can) in the cultures of mouse femoral heads and mouse articular
chondrocytes were analyzed by real-time RT-PCR.
Results: Microarray analyses revealed that 40 and 186 genes had 10-
fold higher expression ratios of AA/AG and IS/ID, respectively, and 16
genes showed 10-fold of both AA/AG and IS/ID ratios. The ratios of the
16 genes were conﬁrmed to be 10 fold by real-time RT-PCR analysis.
Among them three genes were expressed more strongly in AA than in
IS. In these three genes, ﬁbroblast growth factor-18 (Fgf18) was the
extracellular and secreted factor of which the AA/AG ratio was the
highest in the microarray analysis. Immunohistochemistry showed that
Fgf18 was strongly expressed in the articular cartilage chondrocytes of
adult rats but was hardly detected in the growth plate cartilage. In the
rat surgical OA model, a once-weekly intra-articular injection of
recombinant human (rh) FGF18 given 3 weeks post-surgery prevented
cartilage degeneration in a dose-dependent manner at 6 and 9 weeks
after surgery, with a signiﬁcant effect at 10 mg/week of rhFGF18. As an
underlying mechanism, rhFGF18 suppressed the sGAG release into the
culture medium in the ex vivo culture of mouse femoral heads.
Furthermore, rhFGF18 accelerated proliferation and migration of
cultured mouse articular chondrocytes. Among catabolic and anabolic
factors, rhFGF18 decreased Adamts4 and increased Timp1 expressions
in the cultures of mouse femoral heads and murine articular chon-
drocytes, while it decreased Col2a1 and aggrecan expressions in both
cultures.
Conclusions: The present gene expression proﬁling analysis identiﬁed
Fgf18 as a molecule to protect and regenerate adult articular cartilage,
causing prevention of OA development by the intra-articular injection
in a rat model. This effect may be mediated by inhibition of cartilage
catabolism, and acceleration of proliferation and migration of articular
chondrocytes, indicating a possible disease-modifying OA treatment.46
MICRORNAS ARE PROGNOSTIC MARKERS FOR THE CHONDROGENIC
POTENTIAL OF MSCS
N. Georgi y, H. Taipaleenmaki z, A. van Wijnen z, N. Groen y, K. Janaeczek-
Portalska y, C.A. van Blitterswijk y, J. de Boer y, J.N. Post y, M.
Karperien y. yUniv. of Twente, Enschede, Netherlands; zMayo Clinic,
Rochester, MN, USA
Purpose: The capacity of mesenchymal stromal cells (MSCs) to differ-
entiate into chondrocytes as well as to function as trophic mediators
restoring joint homeostasis make them a promising cell source for
a disease modifying treatment in osteoarthritis. MSCs can be easily
harvested from various locations of the body, including amongst others
bone marrow, periosteum, synovium, synovial ﬂuid, adipose tissue,
buccal fat pad, infrapatellar fat pad and osteoarthritic cartilage. MSCs
are a heterogeneous cell population and large inter-donor variation
with respect of the chondrogenic potential of these cells has been re-
ported which may hamper clinical application. Presently, prognostic
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expandedMSCs derived frommultiple donors are lacking. The objective
of this study is to identify such prognostic markers.
Methods: In this study 20 human MSC donors were tested for their
ability to produce cartilage in a standard chondrogenic differentiation
assay consisting of pellet culture in the presence of serum free medium
and TGFb. Cartilage formation was scored on the basis of histological
matrix formation, mRNA expression levels of chondrogenic marker
genes and quantiﬁcation of glycosaminoglycan deposition. Of each of
these donors genome wide mRNA expression proﬁles were obtained
using an affymetrix microarray platform before the onset of differen-
tiation. In addition, small nucleotide RNAs were isolated for miRNA
proﬁling using a panel of miRNAs previously implemented in
chondrogenesis.
Results: Only 3 donors out of 20 were identiﬁed as donors with high
chondrogenic potential, whereas 9 showed moderate and 8 low chon-
drogenic potential. Despite these huge differences in chondrogenic
potential, genome wide mRNA proﬁling at the onset of differentiation
showed only marginal differences between the 3 groups. In contrast,
proﬁling of microRNAs (miRNAs) previously implemented in chondro-
genesis and cartilage homeostasis showed a very distinctive pattern
between good and bad performing donors. We also studied the changes
in miRNA expression during a 7 day differentiation period of MSCs in
pellet culture and identiﬁedmiR-210 andmiR-630 as positive regulators
of chondrogenesis with miR-630 as a potential marker for high per-
forming donors. In contrast miR-181 and miR-34a, both of which are
negative regulators of chondrogenesis, were up-regulated during
differentiation in bad performing donors.
Conclusions: In contrast to themarginal differences at the global mRNA
level between good and bad MSC donors with respect of chondrogenic
differentiation potential, screening of a panel of miRNAs previously
implemented in cartilage formation showed more clear segregation
between good and bad performing donors. MiRNA proﬁling of MSC
donors may, therefore, have prognostic value to select MSC donors with
respect of their chondrogenic differentiation potential and their
capacity to restore cartilage homeostasis after intra-articular injection
in the osteoarthritic joint.47
THE REPAIR OF FOCAL CARTILAGE DEFECTS USING HUMAN
EMBRYONIC STEM CELLS
A. Cheng, T. Hardingham, S. Kimber. Univ. of Manchester, Manchester,
United Kingdom
Purpose: Damage to articular cartilage occurs frequently as a result of
joint trauma and disease. Cell based treatments to repair defects have
been developed using autologous chondrocytes and bone marrow stem
cells and have shown some success.We have investigated the potential of
human embryonic stem cells (hESC) as a source of chondrocytes, as they
have capacity for unlimited self-renewal and could provide a ready supply
of donor cells. In initialworkwe developed a 14 day culture protocol using
serum free, chemically deﬁned medium and generated chondro-
progenitors from hESC, which were up to 97% SOX9 positive, expressing
COL2A1 and ACAN genes. This system is chemically deﬁned and scalable
and with potential to provide cells for clinical grade use. In this study we
developed the protocol further and tested hESC derived chondro-
progenitors in vivo in focal defects in immunocompromised nude rats.
Methods: Human embryonic stem cells (hESC) expanded on feeder
culturewere transferred to feeder free/ serum free culture on ﬁbronectin
coated plates. After two passages a 14 day chondrogenesis protocol was
initiatedwith a sequential series of growth factors,whichdrive thehESCs
through mesendoderm/mesoderm to chondroprogenitors. These cells
were characterised by qRT-PCR using a range of chondrocyte speciﬁc
marker genes, negative controls and by immunoﬂuorescence for SOX9,
a chondrocyte transcription factor. Some chondro-progenitors were also
derived from hESC transduced with GFP using lentiviral vectors. To test
their capacity for cartilage formation, chondro-progenitors in ﬁbrin gel
(3X106 cells/ml) were implanted into osteochondral defects (2mm
diameter, 2mm deep, 14 defects in 8 animals) in the patella groove of
nude rats. Joint tissue was removed, decalciﬁed, ﬁxed and sectioned for
histological and immunochemical analysis after 4 weeks or 12 weeks.
Results: The hESC derived chondro-progenitors at the end of the
protocol formed cell clusters and showed chondrocyte properties,
including high expression of SOX9. They strongly immunostained forSOX9 protein and for collagen II and for aggrecan and expressed
collagen II and XI genes, but not collagen I and negligible collagen X,
which is a marker for hypertrophic chondrocytes. The expression of
matrilin 3 increased and was more than 50 time higher than matrilin 1
at the end of the protocol, again suggesting an articular rather than an
epiphyseal phenotype. Also, we found the expression of core band
factor beta (CBF-beta) was elevated and ZNF145, ZNF219, p300 and
SirT1 were also increased. Defects in nude rat joints were seeded with
chondro-progenitors (approx 2 x105cells per defect) in ﬁbrin gel and in
a contralateral control, ﬁbrin gel alone. Joint tissue was isolated at 4
weeks and 12 weeks and in these preliminary experiments histology
showed evidence of repair cartilage ﬁlling in the defect areas in the cell
seeded joints (cartilage in 2 from 3 animals at 4 weeks and in 2 from 4
animals at 12 weeks). When GFP cells were implanted they were
detected by ﬂuorescence within areas of neo-cartilage formation and
immunohistology using anti human vimentin antibody conﬁrmed
human cells in the repair tissue, which stained with safranin O for
proteoglycan and immunostained for collagen II. Only ﬁbrous tissuewas
found in the defect areas of joints implanted with ﬁbrin gel only.
Conclusions: Human embryonic stem cells in feeder free, serum free,
chemically deﬁned medium were differentiated into chondrogenic
cells, which when implanted in focal defects in nude rats participated in
the formation of cartilage repair tissue assessed up to 12 weeks. The
study demonstrates that human embryonic stem cells can be efﬁciently
differentiated to produce chondro-progenitors with a protocol that is
suitable for future clinical applications.
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DISEASE MODIFYING, RECEPTOR SELECTIVE ANALOGS OF FGF18 FOR
GLOBAL, ARTICULAR CARTILAGE PRESERVATION AND REPAIR IN
EXPERIMENTAL OSTEOARTHRITIS
A. Yayon y, D. Strauss-Ayali y, E. Rom y, K. Mevorat Kaplan y, L. Niv y, A.
Blom z, W. van den Berg z. y Procore, Nes Ziona, Israel; zRadboud Univ.,
Nijmegen, Netherlands
Purpose: We aimed to study the beneﬁts and potential adverse effects
of FGF18 and FGF18 analogs on joint articular cartilage preservation in
an experimental model for Osteoarthritis (OA).
Methods: A series of genetically engineered isoforms of FGF18, a major
cartilage growth and differentiation factor, were tested in a murine
model for surgically induced Osteoarthritis. OA was induced by trans-
section of the anterior medial meniscotibial ligament in the knee joint,
which causes destabilization. Ligands were selected for their FGF
receptor speciﬁcity, discriminating FGFR2 from FGFR3 signaling in bone
and cartilage. Stabilization and controlled release of the growth factors
were achieved through chemical conjugation to Hyaluronic acid (HA)
which were further enhanced using a novel Fibrin-HA based hydrogel.
Ligands were administered by repeated intra-articular injections into
the murine knee joints according to various regimens.
Results: The capacity of these factors in the preservation and tissue
repair of the various articular cartilage compartments was evident by
histologyand grossmorphology.HA link enhanced thepotency of FGF18.
However, wild type FGF18, particularly when administered as soluble,
free ligand, signiﬁcantly enhanced osteophyte formation and size at all
doses tested. The soluble FGFR3 selective ligand, on the other hand, did
not induce osteophytes formation. Unexpectedly, the Fibrin-HA hydro-
gel by itself conferred a protective effect against damage induced OA.
Conclusions: Our results demonstrate a differential effect of FGF18
analogsdifferent in their FGFreceptoractivationoncartilagepreservation
and remodeling in a murine model of damage induced OA. More specif-
ically we suggest that FGF18 signaling via FGFR2 may be the primary
trigger for enhanced local osteogenic effect and osteophyte formation.49
LOCATION-INDEPENDANT ANALYSIS OF INTRAARTICULAR
SPRIFERMIN EFFECTS ON CARTILAGE STRUCTURE USING ORDERED
VALUES
S. Hellot y, W. Wirth z,x, A. Guermazi {,k, C. Pena Rossi y, F.
Eckstein z,x. yMerck Serono S.A. – Geneva (an afﬁliate of Merck KGaA,
Darmstadt, Germany), Geneva, Switzerland; z Paracelsus Med. Univ.,
Salzburg, Austria; xChondrometrics GmbH, Ainring, Germany; kBoston
Univ., Boston, MA, USA; {Boston Imaging Core Lab (BICL) LLC, Boston,
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